Sagimet Biosciences SGMT 深 滬
等待開盤 09-25 09:30:00 美东时间
9.2203
-1.200
-11.51%
華盛通- 最 高9.99
- 今 開9.71
- 成交量 335.62万股
- 最 低 8.685
- 昨 收 10.42
- 總市值 5.73亿
- 52周最高 11.449
- 市盈率 靜 --
- 換手率 5.40%
- 52周最低 4.50
- 委 比 40.68%
- 總股本 6215.87万
- 歷史最高 20.71
- 量 比 3.08
- 振 幅 12.52%
- 歷史最低 1.73
- 每 手 1
- 風險率 1.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
09-24 21:57
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Eliana Merle upgraded Sagimet Biosciences Inc. (NASDAQ:SGMT) from Equal-Weight t...
09-10 00:40
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
09-09 19:07
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences announced that its management will participate in two upcoming investor conferences: the Cantor 2026 Global Healthcare Conference on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, both in New York. A fireside chat from the Cantor conference will be available on Sagimet’s website, with an archived replay for 90 days. Sagimet is a clinical-stage biopharmaceutical compan...
09-02 11:00
美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developi...
08-25 19:02
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat, an oral FASN inhibitor for moderate to severe acne, is on track to begin enrollment in Q4 2026. Patient screening is expected to start in October 2026, with the first patient enrolled shortly after. The trial plans to enroll approximately 800 U.S. patients, including 450 adolescents, over 6 months. Denifanstat has a novel mechanism of action and aims to provide a...
08-25 11:00
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Inc. granted 260,700 stock options to newly hired employees on August 17, 2026, under Nasdaq Rule 5635(c)(4). The options, priced at the closing price of Series A common stock on the same day, vest over four years with 25% after one year and the rest monthly over 36 months, subject to continued employment.
08-17 20:28
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
